Michael Aaron Morse, MD

Professor of Medicine
Professor in the Department of Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 3233, Durham, NC 27710
Phone (919) 681-3480
Email address morse004@mc.duke.edu

We are studying the use of immune therapies to treat various cancers, including gastrointestinal, breast, and lung cancers and melanoma. These therapies include vaccines based on dendritic cells developed in our laboratory as well as vaccines based on peptides, viral vectors, and DNA plasmids. Our group is also a national leader in the development and use of laboratory assays for demonstrating immunologic responses to cancer vaccines. Finally, we are developing immunotherapies based on adoptive transfer of tumor and viral antigen-specific T cells.

Our current clinical trials include phase I and II studies of immunotherapy for: patients with metastatic malignancies expressing CEA, pancreatic cancer, colorectal cancer, breast cancer, and ovarian cancer, and leukemias following HSCT. My clinical area of expertise is in gastrointestinal oncology, in particular, the treatment of hepatic malignancies, and malignant melanoma.

Key words: dendritic cells, immunotherapy, vaccines, T cells, gastrointestinal oncology, melanoma, hepatoma

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1993 - 1996
  • Medical Resident, Medicine, University of Washington, 1990 - 1993
  • M.D., Yale University, 1990

Publications

Kane, A, Thorpe, MP, Morse, MA, Howard, BA, Oldan, JD, Zhu, J, Wong, TZ, Petry, NA, Reiman, R, and Borges-Neto, S. "Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 59, no. 11 (November 2018): 1708-1713.

PMID
29777005
Full Text

Morse, MA, Sun, W, Kim, R, He, AR, Abada, PB, Mynderse, M, and Finn, RS. "The Role of Angiogenesis in Hepatocellular Carcinoma." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research (October 2018).

PMID
30274981
Full Text

Marano, AL, Clarke, JM, Morse, MA, Shah, A, Barrow, W, Selim, MA, Hall, RP, and Cardones, AR. "Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death (PD)-1 therapy." The British Journal of Dermatology (September 23, 2018).

PMID
30244487
Full Text

Chino, F, Stephens, SJ, Choi, SS, Marin, D, Kim, CY, Morse, MA, Godfrey, DJ, Czito, BG, Willett, CG, and Palta, M. "The role of external beam radiotherapy in the treatment of hepatocellular cancer." Cancer 124, no. 17 (September 2018): 3476-3489. (Review)

PMID
29645076
Full Text

Osada, T, Hartman, ZC, Wei, J, Lei, G, Hobeika, AC, Gwin, WR, Diniz, MA, Spector, N, Clay, TM, Chen, W, Morse, MA, and Lyerly, HK. "Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers." Breast Cancer Research : Bcr 20, no. 1 (August 9, 2018): 90-null.

PMID
30092835
Full Text

Vlahovic, G, Meadows, KL, Hatch, AJ, Jia, J, Nixon, AB, Uronis, HE, Morse, MA, Selim, MA, Crawford, J, Riedel, RF, Zafar, SY, Howard, LA, O'Neill, M, Meadows, JJ, Haley, ST, Arrowood, CC, Rushing, C, Pang, H, and Hurwitz, HI. "A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer." The Oncologist 23, no. 7 (July 2018): 782-790.

PMID
29572245
Full Text

Overman, MJ, Ernstoff, MS, and Morse, MA. "Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management." American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, no. 38 (May 2018): 239-247.

PMID
30231358
Full Text

Evans, MK, Brown, MC, Geradts, J, Bao, X, Robinson, TJ, Jolly, MK, Vermeulen, PB, Palmer, GM, Gromeier, M, Levine, H, Morse, MA, Van Laere, SJ, and Devi, GR. "XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype." Cancer Research 78, no. 7 (April 2018): 1726-1738.

PMID
29351901
Full Text

Cohn, A, Morse, MA, O'Neil, B, Whiting, S, Coeshott, C, Ferraro, J, Bellgrau, D, Apelian, D, and Rodell, TC. "Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial." Journal of Immunotherapy (Hagerstown, Md. : 1997) 41, no. 3 (April 2018): 141-150.

PMID
29528991
Full Text

Overman, MJ, Lonardi, S, Wong, KYM, Lenz, H-J, Gelsomino, F, Aglietta, M, Morse, MA, Van Cutsem, E, McDermott, R, Hill, A, Sawyer, MB, Hendlisz, A, Neyns, B, Svrcek, M, Moss, RA, Ledeine, J-M, Cao, ZA, Kamble, S, Kopetz, S, and André, T. "Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 36, no. 8 (March 2018): 773-779.

PMID
29355075
Full Text

Pages